MedTrace Logo

PRostate Cancer Individual Signature Evaluation Trial in Patients Undergoing Scheduled Prostate Biopsy

NCT00966095 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1200

Last updated 2010-11-25

No results posted yet for this study

Summary

The purpose of this study is to develop and validate a blood-based diagnostic test that will predict prostate biopsy outcome as positive or negative for prostate cancer. Such a test will serve to reduce the number of unnecessary prostate biopsies.

Conditions

Sponsors & Collaborators

  • Source MDx

    lead INDUSTRY

Principal Investigators

  • William Oh, MD · Mt. Sinai School of Medicine

  • Danute "Bunki" Bankaitis-Davis, PhD · Source MDx

  • Lisa Siconolfi, PhD · Source MDx

  • Philip Kantoff, MD · Dana-Farber Cancer Institute

Eligibility

Min Age
40 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00966095 on ClinicalTrials.gov